Skip to content

Net Income at other companies

ALN
Alnylam PharmaceuticalsALNY
$205.99M+1,229%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$8.64M+59.8%
Regenxbio logo
RegenxbioRGNX
-$90.05M-1,580%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$9.86M-364%
Opko Health logo
Opko HealthOPK
-$54.85M+18.9%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$76.06M+16.4%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's net income?
Tectonic Therapeutics (TECX) reported net income of -$25.24M in Q1 2026.
How has Tectonic Therapeutics's net income changed year-over-year?
Tectonic Therapeutics's net income decreased by 58.7% year-over-year, from -$15.91M to -$25.24M.
What is the long-term trend for Tectonic Therapeutics's net income?
Over 4 years (2021 to 2025), Tectonic Therapeutics's net income has grown at a -11.2% compound annual growth rate (CAGR), from -$119.13M to -$74.15M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.